COMP <GO>
ESAB vs TMO // ALTMAN Z-SCORE & DEBT/EQUITY
ESAB Corporation (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: ESAB 5
— TMO 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: TMO
LAST: $74.13 (+4.54%) • MKT CAP: $4.61B
balance-sheet
2.35
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
balance-sheet
4.50
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ESAB VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ESAB | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.10% | 9.30% | +0.80 | ESAB | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.5x | 30.4x | -17.90 | ESAB | /valuation <GO> |
| Free Cash Flow Yield | 4.63% | 2.40% | +2.23 | ESAB | /fcf-yield <GO> |
| Operating Margin | 14.50% | 17.40% | -2.90 | TMO | /operating-margins <GO> |
| Net Profit Margin | 8.00% | 15.10% | -7.10 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 3.70% | 3.90% | -0.20 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.48% | 0.24% | +0.24 | ESAB | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 2.35 | 4.50 | -2.15 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.3 | 62.9 | -2.60 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 0.94 | -0.05 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.9x | 36.3x | -17.40 | ESAB | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.61B | $262.22B | -$257.61B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ESAB REV | TMO REV | ESAB GROSS % | TMO GROSS % | ESAB FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.84B | $44.56B | 36.9% | — | $213.3M | $6.29B |
| FY 2024 | $2.74B | $42.88B | 37.9% | — | $303.6M | $7.27B |
| FY 2023 | $2.77B | $42.86B | — | — | $205.6M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ESAB // BETA 0.89
TMO // BETA 0.94